Tumor Transcriptomics

Global Tumor Transcriptomics Market to Reach US$7.6 Billion by 2030

The global market for Tumor Transcriptomics estimated at US$5.8 Billion in the year 2024, is expected to reach US$7.6 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 7.3% CAGR

The Tumor Transcriptomics market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Tumor Transcriptomics Market - Key Trends & Drivers Summarized

What Is the Role of Transcriptomics in Understanding Tumor Biology?

Tumor transcriptomics decodes active gene expression in cancer cells, revealing how tumors behave and evolve. Unlike static DNA data, transcriptomics captures dynamic molecular events, identifying gene activity that influences tumor growth, metastasis, and therapy resistance.

It`s pivotal in precision medicine, allowing oncologists to customize treatment based on real-time tumor behavior. Single-cell and spatial transcriptomics provide high-resolution maps of cellular differences within tumors, improving the understanding of heterogeneity and guiding therapy.

How Are Technology and Clinical Adoption Expanding the Transcriptomics Frontier?

Technological leaps in sequencing platforms and data analytics have brought transcriptomics into clinical practice. Tools like spatial transcriptomics reveal how different parts of a tumor interact with the surrounding tissue. RNA-based profiling is now being used to match patients with immunotherapies, targeted drugs, or chemotherapies.

Regulatory agencies are approving transcriptomic panels for cancer diagnosis and prognosis. Partnerships between hospitals and biotech firms are accelerating integration into everyday oncology care. AI and cloud platforms are making data interpretation faster and more accessible.

The Growth in the Tumor Transcriptomics Market Is Driven by Several Factors…

Growth is driven by the rise of precision oncology, falling costs of RNA sequencing, and wider clinical adoption. Increasing cancer prevalence and the demand for biomarker-driven therapies are key drivers. Government funding, omics infrastructure investment, and the expanding pipeline of RNA-targeting drugs all contribute to market momentum.

SCOPE OF STUDY:

The report analyzes the Tumor Transcriptomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Consumables, Instruments, Software & Services); Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Tumor Types); Technology (Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology, Other Technologies); Application (Diagnostics & Disease Profiling Application, Drug Discovery Application, Other Applications); End-Use (Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• 10x Genomics
• Agilent Technologies, Inc.
• Akoya Biosciences, Inc.
• Arraystar Inc.
• Bio-Rad Laboratories, Inc.
• BGI Genomics
• CD Genomics
• Cytiva (Danaher)
• F. Hoffmann-La Roche AG
• Fluidigm Corporation (now Standard BioTools)
• GenScript Biotech Corporation
• Illumina, Inc.
• Lexogen GmbH
• NanoString Technologies, Inc.
• Novogene Co., Ltd.
• Oxford Nanopore Technologies
• Qiagen N.V.
• Sequentia Biotech
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.